RANI Rani Therapeutics Holdings, Inc. Insider Trading

Director Imran Mir acquires 2,083,334 shares of RANI at $0.60 for $1,260,417.07; company unprofitable with $-6,692,000 net loss.

Director Imran Mir purchased 2,083,334 shares at $0.60 on 2025-10-23, establishing a substantial new position worth $1,260,417.07 in a company with zero quarterly revenue and a full-year net loss of $-6,692,000. The purchase occurred at a significant discount to both the current trading price of $1.78 (68% discount to current levels) and well below the 52-week high of $2.85, but notably the stock has experienced a 30-day rally of +270.8% before this filing, suggesting the transaction may not represent an entry point at depressed levels. For an unprofitable clinical-stage biotech, the outsized accumulation by a director warrants scrutiny into whether this reflects confidence in pending developments (trials, partnerships, regulatory progress) or other material nonpublic information not yet disclosed in SEC filings.

10% owner sold 5.92M shares for $15.7M across two days (Oct 20-21) at $2.41-$2.77; exits 71.3% of position

South Cone Investments Limited Partnership executed 2 separate sales totaling 5,923,000 shares for $15,711,314.50 at a blended average price of $2.65, reducing its position from 8,302,194 shares to 2,379,194 shares. The timing merits attention: the insider's prior two sales at RANI (October 2024) both posted negative 90-day returns (-7.9% and -27.8% respectively), consistent with a 100% well-timed sell rate across his cross-ticker history (avg 90d return post-sale: -54.6%). The company is unprofitable with net income of $-6,692,000 for the latest period and zero revenue recognition in the most recent quarter, presenting fundamental headwinds. Against this, RANI stock has surged +387.5% over the past 30 days and +382.6% over 90 days, now trading at $2.42—only 15.1% below its 52-week high of $2.85—which may explain the material reduction in an already-concentrated stake.

CBOwallace McKinley Kate buys 17,960 shares (18.0K) of RANI at $1.67; stock down -79.8% YTD, company burning cash with $-6.8M net loss.

McKinley Kate, Chief Business Officer, purchased 17,960 shares at $1.67 on 2024-12-13, establishing an initial position in RANI. The transaction occurs in severe fundamental distress: the company reported $0.00 revenue in the latest quarter, a net loss of $-6.8M, and experienced -100.0% annual revenue growth. The stock has collapsed -79.8% from its 52-week high of $7.85 and is down -30.0% over the preceding 30 days. An insider purchase by a senior executive in a revenue-depleted, loss-generating company trading at multi-year lows merits investor scrutiny of both the company's operational trajectory and the CBOs rationale for the investment at this valuation.

CEO Imran Talat bought 10,296 shares of RANI at $1.94 on 2024-12-09; stock down 75.8% from 52-week high, company unprofitable with -$6.8M net income.

Imran Talat, as CEO, purchased 10,296 shares at $1.94 on 2024-12-09, bringing his post-transaction holdings to 494.8K shares. This open-market buy comes as RANI trades at $1.90 current price, down 75.8% from its 52-week high of $7.85, and the stock has declined 21.2% over the past 30 days and 22.8% over 90 days. The company's fundamentals are severely stressed: revenue is $0.00 in the latest quarter, with a net loss of $-6.8M annually and negative 100.0% annual revenue growth. Notably, Imran Talat's prior 5 buys at RANI (all conducted in November and December 2023) demonstrated strong 90-day timing outcomes, with average 90d returns of +62.4%, though those purchases occurred 12+ months ago when valuations were materially higher. The extreme price deterioration since those prior trades and the company's cash-consumption profile without revenue generation represent a fundamentally different risk environment than his prior purchase windows at this ticker.

10% owner South Cone Investments sells 3,829,360 shares (31.6% of holdings) for $10.1M at blended avg $2.65

South Cone Investments Limited Partnership, a 10% shareholder, executed 2 separate sales totaling 3,829,360 shares for $10,141,673.59 on 2024-10-15, reducing its stake from 12,131,554 to 8,302,194 shares. The blended average sale price of $2.65 sits near current price of $2.63, and the stock is -66.5% from its 52-week high of $7.85. Against this backdrop, the company reported Revenue $0.00 in the latest quarter and Net income $-6,805,000.00, with Annual revenue growth of -100.0%, signaling severe operational distress. While the insider's prior buy at this ticker on 2023-11-24 achieved a 90-day return of +62.2%, the current substantial reduction in stake—eliminating nearly one-third of holdings—during a period of zero revenue and significant losses represents a material shift in the insider's commitment to the security.